<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602470</url>
  </required_header>
  <id_info>
    <org_study_id>18575</org_study_id>
    <nct_id>NCT02602470</nct_id>
  </id_info>
  <brief_title>Preferences &amp; Treatment Satisfaction Drivers in Rosacea Patients</brief_title>
  <official_title>A Study of Patient Preferences and Drivers of Treatment Satisfaction in Patients With Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To survey patients with rosacea about their rosacea treatment preferences as well as to
      assess potential drivers of rosacea treatment satisfaction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2015</start_date>
  <completion_date type="Actual">March 10, 2016</completion_date>
  <primary_completion_date type="Actual">March 10, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported concerns and importance of such concerns regarding their current topical rosacea treatments</measure>
    <time_frame>Rosacea treatment in the past 4 weeks</time_frame>
    <description>Assessed from the Rosacea Treatment Preference Questionnaire:
Rated on a scale of 0 to 10, with 0 meaning not at all important and 10 meaning extremely important</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported likelihood of switching to a topical rosacea treatments</measure>
    <time_frame>Rosacea treatment in the past 4 weeks</time_frame>
    <description>Assessed from the Rosacea Treatment Preference Questionnaire:
Rated on a scale of 0 to 10, with 0 meaning not at all likely and 10 meaning extremely likely</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Rosacea treatment in the past 4 weeks</time_frame>
    <description>Measured using Dermatology Life Quality Index (DLQI):
The DLQI consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, and school, personal relationships and treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>Rosacea treatment in the past 4 weeks</time_frame>
    <description>Assessed by a score on the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q). Scores will be standardized and expressed as a 0-100 standardized score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported concerns and importance (a rating scale) of such concerns that patients would consider when switching to a new topical rosacea treatment</measure>
    <time_frame>Rosacea treatment in the past 4 weeks</time_frame>
    <description>Extracted from the Rosacea Treatment Preference Questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Baseline demographics and clinical characteristics: Age</measure>
    <time_frame>Retrospective database analysis: encompassing patient data from up to 5 years</time_frame>
    <description>Assessed from retrospective analysis of electronic medical records</description>
  </other_outcome>
  <other_outcome>
    <measure>Baseline demographics and clinical characteristics: Gender</measure>
    <time_frame>Retrospective database analysis: encompassing patient data from up to 5 years</time_frame>
    <description>Assessed from retrospective analysis of electronic medical records</description>
  </other_outcome>
  <other_outcome>
    <measure>Baseline demographics and clinical characteristics: Insurance type</measure>
    <time_frame>Retrospective database analysis: encompassing patient data from up to 5 years</time_frame>
    <description>Assessed from retrospective analysis of electronic medical records</description>
  </other_outcome>
  <other_outcome>
    <measure>Baseline demographics and clinical characteristics: Charlson Comorbidity Index (CCI)</measure>
    <time_frame>Retrospective database analysis: encompassing patient data from up to 5 years</time_frame>
    <description>Assessed from retrospective analysis of electronic medical records</description>
  </other_outcome>
  <other_outcome>
    <measure>Baseline demographics and clinical characteristics: Rosacea-relevant comorbidities and complications</measure>
    <time_frame>Retrospective database analysis: encompassing patient data from up to 5 years</time_frame>
    <description>Assessed from retrospective analysis of electronic medical records:
Blepharitis (ICD-9: 373.0) Conjunctivitis (ICD-9: 372.0-372.2) Corneal neovascularization / keratitis (ICD-9: 370) Depression (ICD-9: 296.2-296.3) Migraine (ICD-9: 346)</description>
  </other_outcome>
  <other_outcome>
    <measure>Baseline demographics and clinical characteristics: Rosacea treatment-related adverse events</measure>
    <time_frame>Retrospective database analysis: encompassing patient data from up to 5 years</time_frame>
    <description>Assessed from retrospective analysis of electronic medical records:
Burning/stinging/tingling (ICD-9: 782.0) Pruritus (ICD-9: 698) Scaling/dry skin/xerosis (ICD-9: 692.9, 706.8) Erythema/irritation (ICD-9: 695) Contact dermatitis (ICD-9: 692.3, 692.8, 692.9) Facial edema (ICD-9: 782.3) Acne (ICD-9: 706.1)</description>
  </other_outcome>
  <other_outcome>
    <measure>Current and past medication use</measure>
    <time_frame>Retrospective database analysis: encompassing patient data from up to 5 years</time_frame>
    <description>Assessed from retrospective analysis of electronic medical records
Including:
azelaic acid gel, azelaic acid cream, metronidazole gel, metronidazole cream, metronidazole lotion, metronidazole emulsion, brimonidine tartrate gel</description>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported adverse events associated with patients' satisfaction/dissatisfaction</measure>
    <time_frame>Rosacea treatment in the past 4 weeks</time_frame>
    <description>Assessed from the Rosacea Treatment Preference Questionnaire:
Rated on a scale of 0 to 10, with 0 meaning no pain/discomfort and 10 meaning unbearable pain/discomfort</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">206</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Rosacea treated patients</arm_group_label>
    <description>Patients using topical rosacea treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)</intervention_name>
    <description>Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser &amp; Moisturizing</description>
    <arm_group_label>Rosacea treated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic Acid Cream</intervention_name>
    <description>Azelaic Acid Cream 20%</description>
    <arm_group_label>Rosacea treated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole gel</intervention_name>
    <description>Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser</description>
    <arm_group_label>Rosacea treated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole cream</intervention_name>
    <description>Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser</description>
    <arm_group_label>Rosacea treated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Emulsion</intervention_name>
    <description>Metronidazole Emulsion 0.75%</description>
    <arm_group_label>Rosacea treated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Lotion</intervention_name>
    <description>Metronidazole Lotion 0,75%</description>
    <arm_group_label>Rosacea treated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine Tartrate Gel</intervention_name>
    <description>Brimonidine Tartrate Gel 0.33%</description>
    <arm_group_label>Rosacea treated patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are using topical rosacea treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients of at least 18 years of age at index date

          -  At least one prescription for a topical rosacea treatments: Azelaic Acid Gel, Azelaic
             Acid Cream, Metronidazole Gel, Metronidazole Cream, Metronidazole Emulsion,
             Metronidazole Lotion, Brimonidine Tartrate Gel

          -  At least one medical record with a diagnosis code for rosacea (ICD-9: 695.3)

          -  At least 6 months of data history prior to the index date

          -  Had at least one encounter at the Reliant Medical Group within 3 months prior to 01
             January 2015

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

